Recently, we at Novus Biologicals became partners with Strategic Diagnostics Inc (SDIX), one of the largest antibodyproducers in the US. The objective was to extend our antibody database by over 800 of SDIX's polyclonal cancer antibodies, created by their unique Genomic Antibody Technology (GAT) system, as well as creating novel GAT immunoglobulins against targets specific to our own antibody catalog. However, what exactly is GAT, and why is it so superior?
With ever more sophisticated assay testing and data retrieval techniques becoming established in the life sciences arena, it’s obvious the reagents must be of a similar quality. In cancer studies especially, it is alterations in protein structure which scientists are looking for. To separate potential oncogenes from normal, non-cancer causing proteins, it’s important that the targets for which antibodies are developed are as near their natural state as possible.
Western Blot: GAT1 Antibody
Using Genomic Antibody Technology, a large variety of antibodies targeted to antigens in their naturally folded forms has been developed. This is because the antibodies are produced in vivo so that they are able to develop and form accurately and with their natural functions. As more proteins are discovered, GAT antibodies can be added to our database. Creating a system by which any immunoglobulin can recognize a protein in its natural folded state is a tremendous advantage to clinical research. Proteins that were previously of restricted value can now be used in highly valuable assay areas such as chromatin immunoprecipitation (ChIP), sandwich immunoassays and flow cytometry.
Another advantage to GAT is its ability to create reagents against difficult target antigens, such as highly conserved nucleic acid sequences. The development of Genomic Antibody Technology is a tremendous step forward, considerably enhancing an already extensive antibody catalog.
Novus Biologicals offers many GAT reagents for your research needs including:
